Whoopi Goldberg issues warning about fake social media ad of her endorsing weight loss treatment
Whoopi Goldberg issues warning about fake social media ad of her endorsing weight loss treatment - ‘The View’ host previously ...
Whoopi Goldberg Warns Against AI-Created Ad Using Her Image to Sell Weight-Loss Drug: ‘Do Not Fall for It!’
EGOT winner Whoopi Goldberg railed against an ad that's circulating on social media with a manipulated version of her ...
Sharon Osbourne emerges for the first time in months as she announces Black Sabbath reunion - after admitting she's still suffering Ozempic side effects despite q…
Sharon was on hand to promote the event alongside the band's originals guitarist Tony Iommi, after admitting she is ...
Hosted on MSN1h
Whoopi Goldberg addresses 'phony weight-loss ad' showing her selling weight-loss drugs during 'The View'
"The View" co-host Whoopi Goldberg hit back at a fake ad she's seen on Instagram, depicting her supporting a "bad" weight loss drug on Wednesday, asking viewers to not engage with the ad.
BioPharma Dive3h
Novo outlines new late-stage study of obesity drug CagriSema
CagriSema, which underperformed expectations in its first Phase 3 test, will be studied at different doses and for longer ...
Novo Nordisk: Among The Best Opportunities Of The Moment (Rating Upgrade)
Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.
Study warns diabetic 'yo-yo' dieting can hurt kidneys in those with type 1 diabetes
"Yo-yo" dieting --- repeatedly losing and gaining weight -- can significantly increase risk of kidney disease among people ...
STAT5h
Pharmalittle: We’re reading about an FDA hold on an Amgen obesity drug, imported Canadian drugs, and more
The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight ...
Novo Nordisk defends next-gen obesity drug CagriSema, gives details of new trial
Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...
Prescriptions for weight loss drugs are skyrocketing, especially among young women. Experts think they know why.
The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...
Lilly needs a plan to spur weight-loss drug sales, investors say
Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...
Novo Nordisk sales beat estimates, but the story wasn’t Ozempic
Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t ...